Therapeutic Asset Ratings

205 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Pumitamig Lung Cancer	Bristol-Myers Squibb	P1/2	CC (41)
RECOMBINANT FULLY HUMAN IGG1 KAPPA ANTI-TIGIT MONOCLONAL ANTIBODY EOS-448 Lung Cancer	iTeos Belgium SA	P1/2	CC (41)
Rezatapopt Lung Cancer	PMV Pharmaceuticals, Inc	P1/2	CC (41)
Sugemalimab Lung Cancer	Sichuan University	P1/2	CC (41)
t3011 Lung Cancer	ImmVira Pharma Co. Ltd	P1/2	CC (41)
tng260 Lung Cancer	Tango Therapeutics, Inc.	P1/2	CC (41)
tng456 Lung Cancer	Tango Therapeutics, Inc.	P1/2	CC (41)
tng462 Lung Cancer	Tango Therapeutics, Inc.	P1/2	CC (41)
Valemetostat Lung Cancer	National Cancer Institute (NCI)	P1/2	CC (41)
Vofatamab Lung Cancer	Fusion Pharmaceuticals Inc.	P1/2	CC (41)
Autologous Dendritic Cell-Adenovirus Ccl21 Vaccine Lung Cancer	Jonsson Comprehensive Cancer Center	P1	CC (40)
bi 765049 Lung Cancer	Boehringer Ingelheim	P1	CC (40)
Carotuximab Lung Cancer	Karen Reckamp, MD, MS	P1	CC (40)
Cnsi-Fe Lung Cancer	Sichuan Enray Pharmaceutical Sciences Company	P1	CC (40)
Ezabenlimab Lung Cancer	Boehringer Ingelheim	P1	CC (40)
Palbociclib Lung Cancer	Lebanese University	P1	CC (40)
Sonidegib Lung Cancer	Mayo Clinic	P1	CC (40)
NC 410 Lung Cancer	NextCure, Inc.	P1/2	CC (40)
PRT1419 Lung Cancer	Prelude Therapeutics	P1	C (39)
[177lu]lu-evs459 Lung Cancer	Novartis Pharmaceuticals	P1	C (37)
18f-αvβ6-bp Lung Cancer	University of California, Davis	P1	C (37)
[68ga]ga-evs459 Lung Cancer	Novartis Pharmaceuticals	P1	C (37)
bg-60366 Lung Cancer	BeOne Medicines	P1	C (37)
Bl-M07D1 Lung Cancer	SystImmune Inc.	P1	C (37)
Brodalumab Lung Cancer	Brian Henick, MD	P1	C (37)

Showing 126 to 150 of 205 assets